An Open-label, 2-Period, 2-Sequence Cross-over Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin in Healthy Participants
Latest Information Update: 04 Apr 2025
At a glance
- Drugs AZD 0780 (Primary) ; Rosuvastatin (Primary)
- Indications Dyslipidaemias
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 31 Mar 2025 According to a AstraZeneca media release, findings from this study were presented at the European Atherosclerosis Society (EAS) 2024.
- 30 May 2023 Status changed from recruiting to completed.
- 03 Apr 2023 New trial record